Of the therapeutically important cardiac glycosides, ouabain is the only one for which the exact structure of the aglycone (ouabagenin) still has to be established. Ouabain was discovered and so named by Arnaud (1) who in 1888 isolated from the bark and roots of the ouabaio tree (Acokanthera ouabaio) a toxic glycoside which was used by the Somalis of East Africa as an arrow poison. Later ( 2 ) he found the same glycoside in another arrow poison, the in6e or onaye of the Pahouins which was prepared from the seeds of Strophanthus gratus (S. glaber). The name g-strophanthin, introduced by Thoms (3, pp. 114, 119) to distinguish it from the strophanthins of other species, is frequently used in the German literature for ouabain. Of all cardiac active principles, ouabain is the most easily obtainable since it can be isolated and crystallized from the seeds of Strophanthus gratus in 5 % yield (4).As early as 1898 Arnaud (5) identified rhamnose as the sugar moiety of ouabain.Efforts to prepare the true aglycone (ouabagenin) remained fruitless for a long period of time. Various modifications of acid and enzymatic hydrolysis had yielded only resins which were the result of dehydration and possibly simultaneous polymerization. It was a major accomplishment when in 1942 Mannich and Siewert (4) succeeded in preparing the true crystalline aglycone by hydrolysis of its acetonide which in turn had been obtained by treatment of the glycoside with small amounts of concentrated hydrochloric acid in acetone. The early investigators, therefore, studied the crystalline glycoside rather than the altered aglycone. Jacobs (6) established for ouabain the formula CaH44012.